RESMED INC
About RESMED INC
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $5.1B
- Net income
- $1.4B
- Total assets
- $8.2B
- Market cap
- $28.4B
- Gross margin
- 59.4%
- Operating margin
- 32.7%
- Net margin
- 27.2%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $5.1B
- Cost of revenue
- $2.1B
- Gross profit
- $3.1B
- Operating expenses
- $1.4B
- Operating income
- $1.7B
- Income tax
- $276.8M
- Net income
- $1.4B
- EPS (basic)
- $9.55
- EPS (diluted)
- $9.51
Balance sheet
- Total assets
- $8.2B
- Current assets
- $3.5B
- Total liabilities
- $2.2B
- Current liabilities
- $1.0B
- Shareholders’ equity
- $6.0B
Cash flow
- Operating cash flow
- $1.8B
- Investing cash flow
- -$200.0M
- Financing cash flow
- -$606.3M
- Net cash flow
- $971.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $28.4B
- P/E ratio
- 20.4
- EPS (diluted)
- $9.51
- Dividend yield
- 1.24%
- Shares outstanding
- 146.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 2, 1995
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $1.4B in FY2025.
- Revenue grew 61% from FY2021 to FY2025.
- Gross margin of 59.4%, net margin 27.2%.
- Trading 34% below its 52-week high.
- Pays a dividend yielding about 1.24% annually.
- Valued at a price-to-earnings (P/E) ratio of 20.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review RESMED INC.
Write a review
News about RESMED INC
News & sentiment via Polygon.io
